课题基金 / 基金详情

项目摘要

项目成果

TATIANA M. FOROUD的其他基金

相似基金

相关文献

中文摘要
翻译
摘要-生物医学/病理学核心 这个孢子的首要目标是了解高活性的p21ras的生物学基础。 通路信号在儿童恶性神经纤维瘤病1型发病机制中的作用 把治疗带到诊所去。每个项目都使用不同的疾病模型来探索这一主题。然而,所有项目 将人类、小鼠和体外研究相结合,以确定改变RAS效应的因素。为了确保 如果这些研究取得成功,将使用互补的尖端技术来解决关键问题 与疾病易感性、疾病复发的可能性和其他恶性肿瘤的风险有关。 生物学家和病理学核心将从所有四个项目中接收人类和老鼠样本 孢子。核心还将提供所有样本的病理检查,并将这些数据提供给所有人 孢子调查人员和更广泛的研究社区。这一核心的具体目标是: 目标1:维护和更新DHART孢子网站,作为一个有效的内部和外部 沟通工具。 目标2:对作为部分收集的样本采用统一的生物检疫接收、跟踪和分发程序 达特孢子项目。 目的3:对人类和动物样本进行统一的病理学鉴定 作为DHART孢子项目的一部分收集。
英文摘要
ABSTRACT – BIOSPECIMEN/PATHOLOGY CORE The overarching goal of this SPORE is to understand the biological underpinnings of hyperactivated p21ras pathway signals in the pathogenesis of childhood malignancies of neurofibromatosis type 1 and to bring new therapies to the clinic. Each project explores this theme using a different disease model. However, all projects interweave human, mouse and in vitro studies to identify factors that modify the effects of Ras. To ensure the success of these studies, complementary cutting-edge technologies will be used to address key questions related to disease susceptibility, likelihood of disease relapse, and risk for other malignancies. The Biospecimen and Pathology Core will receive human and mouse samples from all four projects in the SPORE. The core will also provide pathological review of all samples and will make these data available to all SPORE investigators and the broader research community. The specific aims of this core are: Aim 1: Maintain and update the DHART SPORE website as an effective internal and external communication tool. Aim 2: Utilize uniform biospecimen receipt, tracking and distribution procedures for samples collected as part of DHART SPORE projects. Aim 3: Apply uniform pathology protocols for the characterization of human and animal samples collected as part of DHART SPORE projects.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Biospecimen Exchange for Neurological Disorders (BioSEND)
Genetic, Biomarker and Biospecimen Core
Genetic, Biomarker and Biospecimen Core
Biospecimen Exchange for Neurological Disorders (BioSEND)
海外基金